Bio-Rad Laboratories, Inc.
NYSE:BIOMedical - Devices
-$0.65 today
- Market cap
- $9.95B
- Beta
- 1.08
- P/E (TTM)
- 45.4
- EPS (TTM)
- $6.26
Volume 0.46M
Average 0.38M
BIO Total Liabilities
Everything the company owes to creditors and other parties.
Bio-Rad Laboratories, Inc.NYSE: BIO
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities broadly unchanged from a year ago
Total liabilities stood at $3.08B at the end of Q2 FY2026, down 0.2% from a year earlier and up 4.7% from the prior quarter. Over 3 fiscal years it compounded at -7.0% a year.
Context
- Total liabilities amounted to 30.0% of total assets at the end of Q2 FY2026, down 0.2 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -0.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 3.12B USD
- Year-over-year change
- +11.7%
- 4-year CAGR
- -6.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.12B | +11.7% |
| FY2024 | 2024-12-31 | 2.79B | -21.4% |
| FY2023 | 2023-12-31 | 3.56B | -8.5% |
| FY2022 | 2022-12-31 | 3.89B | -5.5% |
| FY2021 | 2021-12-31 | 4.11B | — |
Total Liabilities vs competitors
How BIO compares with its peers on the latest reported figures
- BIO's Jun 2026 total liabilities of $3.08B is the 5th highest of the 11 companies compared; the peer median is $809.07M.
- Its year-over-year change of -0.2% is the 6th highest of 11, against a peer median of -3.5%.
- Total liabilities amounts to 30.0% of total assets for BIO, versus a peer median of 40.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $59.47B | +14.7% | +2.3% | 52.1% | |
| Sep 2026 | $39.66B | +37.6% | -3.4% | 42.5% | |
| Jul 2026 | $4.82B | +0.2% | -10.0% | 40.0% | |
| Jun 2026 | $3.63B | -18.8% | +14.6% | 60.0% | |
| Jun 2026 | $3.08B | -0.2% | -7.0% | 30.0% | |
| Jun 2026 | $838.15M | -0.2% | +10.8% | 28.4% | |
| Mar 2026 | $780M | +1.4% | -13.5% | 99.7% | |
| Sep 2026 | $471.13M | -15.9% | -5.3% | 17.9% | |
| Sep 2026 | $311.16M | -6.7% | -4.0% | 18.2% | |
| Jun 2026 | $248.16M | -42.2% | -33.9% | 41.1% | |
| Mar 2026 | $77.99M | -37.6% | -32.8% | 12.2% | |
| Peer median (excluding BIO) | $809.07M | -3.5% | -4.6% | 40.5% | |
Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 470.78M | 434.22M | 403.8M | 488.1M | 531.8M |
| Short-term Investments | 399.14M | 1.36B | 1.2B | 1.18B | 1.01B |
| Net Receivables | 423.54M | 494.65M | 489M | 452.5M | 472.5M |
| Inventory | 572.24M | 719.32M | 780.5M | 760M | 740.7M |
| Other Current Assets | 15.65M | 29.16M | 31.7M | 30.7M | 13.8M |
| Total Current Assets | 1.99B | 3.16B | 3.05B | 3.03B | 2.91B |
| Property, Plant & Equipment (Net) | 716.44M | 679.55M | 723.7M | 688.6M | 709.9M |
| Goodwill | 347.3M | 406.5M | 413.6M | 410.5M | 579.8M |
| Intangible Assets | 253.9M | 332.1M | 320.5M | 293.6M | 174.3M |
| Long-term Investments | 14.39B | 8.83B | 7.7B | 4.84B | 6.1B |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 104.19M | 94.6M | 94.9M | 101.9M | 102.3M |
| Total Non-current Assets | 15.81B | 10.34B | 9.25B | 6.33B | 7.67B |
| Total Assets | 17.8B | 13.5B | 12.3B | 9.36B | 10.58B |
| Account Payables | 141.94M | 135.04M | 144.6M | 122.3M | 129M |
| Short-term Debt | 489K | 465K | 500K | 1.2M | 37.9M |
| Tax Payables | 46.3M | 32.43M | 35.8M | 31.2M | 36.6M |
| Deferred Revenue | 50.85M | 52.21M | 0 | 0 | 0 |
| Other Current Liabilities | 127.94M | 117.44M | 161.6M | 147.2M | 141.2M |
| Total Current Liabilities | 680.94M | 568.71M | 522.8M | 467.8M | 517M |
| Long-term Debt | 10.51M | 1.2B | 1.2B | 1.2B | 1.34B |
| Deferred Tax Liabilities | 3.06B | 1.77B | 1.48B | 818M | 1.06B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 182.19M | 195.93M | 195M | 177.2M | 53.4M |
| Total Non-current Liabilities | 3.43B | 3.32B | 3.04B | 2.33B | 2.61B |
| Total Liabilities | 4.11B | 3.89B | 3.56B | 2.79B | 3.12B |
| Common Stock | 3K | 3K | 0 | 0 | 0 |
| Retained Earnings | 13.53B | 9.9B | 9.26B | 7.42B | 8.18B |
| Accumulated OCI | (175.55M) | (466.82M) | (336M) | (538.2M) | (189.1M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 13.69B | 9.62B | 8.74B | 6.57B | 7.45B |
| Total Debt | 223.38M | 1.39B | 1.41B | 1.37B | 1.53B |
| Net Debt | (247.41M) | 953.88M | 1B | 886.6M | 999.2M |
Bio-Rad Laboratories, Inc.
NYSE:BIO
Intrinsic Alpha fair value
Locked
Current Price
$370.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.